ArticleACS synthetic biology2023
Cell Free Bacteriophage Synthesis from Engineered Strains Improves Yield.
Article in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Single-step monolithic chromatography efficiently purifies diverse Pseudomonas aeruginosa phages with therapeutic-grade endotoxin reduction.Npj viruses · 2026Article
- Cell-free synthesis and characterization of Salmonella, Escherichia coli, and Shigella-specific bacteriophages.Microbial cell factories · 2026Article
- Phages for One Health: regulatory and product life cycle considerations.Microbiology (Reading, England) · 2026Review
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- Characterization and purification of Pseudomonas aeruginosa phages for the treatment of canine infections.BMC microbiology · 2025Article
- Bacillus subtilis surface display technology: applications in bioprocessing and sustainable manufacturing.Biotechnology for biofuels and bioproducts · 2025Review
- Cell-free expression system: a promising platform for bacteriophage production and engineering.Microbial cell factories · 2025Review
- Synthetic cells for phage therapy: a perspective.Frontiers in cellular and infection microbiology · 2025Review
- Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections.Frontiers in pharmacology · 2025Article
- Profiling expression strategies for a type III polyketide synthase in a lysate-based, cell-free system.Scientific reports · 2024Article
- Between Centralization and Fragmentation: The Past, Present, and Future of Phage Collections.PHAGE (New Rochelle, N.Y.) · 2024Review
- The Biotechnological Application of Bacteriophages: What to Do and Where to Go in the Middle of the Post-Antibiotic Era.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage therapy to treat life-threatening drug-resistant infections has been hampered by technical challenges in phage production. Cell-free bacteriophage synthesis (CFBS) can overcome the limitations of standard phage production methods by manufacturing phage virions in vitro. CFBS mimics intracellular phage assembly using transcription/translation machinery (TXTL) harvested from bacterial lysates and combined with reagents to synthesize proteins encoded by a phage genomic DNA template. These systems may enable rapid phage production and engineering to accelerate phages from bench-to-bedside. TXTL harvested from wild type or commonly used bacterial strains was not optimized for bacteriophage production. Here, we demonstrate that TXTL from genetically modified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.